article Open AccessTop 1% cited

Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

PLoS Medicine · 2008 · Vol. 5(12) · pp. e232–e232

Martin Köbel(Vancouver General Hospital)Steve E. Kalloger(BC Cancer Agency)Niki Boyd(BC Cancer Agency)Steven McKinney(BC Cancer Agency)Erika Mehl(BC Cancer Agency)Chana Palmer(Canary Foundation)Samuel Leung(BC Cancer Agency)Nathan J. Bowen(Georgia Institute of Technology)Diana N. Ionescu(Vancouver General Hospital)Ashish Rajput(Vancouver General Hospital)Leah Prentice(BC Cancer Agency)Dianne Miller(BC Cancer Agency)Jennifer L. Santos(BC Cancer Agency)Kenneth D. Swenerton(BC Cancer Agency)C. Blake Gilks(BC Cancer Agency)David G. Huntsman✉(BC Cancer Agency)

View via DOI Publisher page

Abstract

The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.

Ovarian cancer diagnosis and treatment Endometriosis Research and Treatment Circular RNAs in diseasesBiomarkerSerous fluidOncologySerous carcinomaOvarian cancerClear cellInternal medicineMedicinePopulationOvarian carcinoma

MeSH terms

CarcinomaDiagnosis, DifferentialFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingOvarian DiseasesOvarian NeoplasmsPrognosisRetrospective StudiesBiomarkers, TumorCohort StudiesConfounding Factors, EpidemiologicSurvival Analysis